Medtronic (NYSE:MDT) last week told patients that it plans to sunset its Sof-sensor glucose sensor as of Dec. 1 and move patients to its newer Enlite device.
In a Sept. 30 notice, Fridley, Minn.-based Medtronic said it’s discontinuing the Sof-sensor, its oldest continuous glucose monitoring sensor, isn’t related to the sensor’s safety or performance.
“Our business is dedicated to introducing new technologies with advanced therapeutic benefits. In order to make our future technology available to you, we must ensure only our most advanced sensor technology remains on the market,” the company said.
Medtronic is offering to convert patients to its MiniMed 530G, which uses the Enlite CGM system, for no out-of-pocket costs. The decision means that Medtronic will no longer have a CGM sensor for patients under age 16, the company said, pledging to 3 months worth of Sof-sensors at no charge.
“Please know we did not reach the decision to discontinue Sof-sensor easily. As we prepare to pave the way for new products with improved therapeutic benefit, we must ensure only our most advanced CGM sensor technology remains on the market. As a result, we have found it necessary to discontinue Sof-sensor, our oldest CGM sensor,” the company wrote.